{"id":"https://openalex.org/W2328015443","doi":"https://doi.org/10.1158/1538-7445.am2012-5696","title":"Abstract 5696: Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11)","display_name":"Abstract 5696: Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11)","publication_year":2012,"publication_date":"2012-04-01","ids":{"openalex":"https://openalex.org/W2328015443","doi":"https://doi.org/10.1158/1538-7445.am2012-5696","mag":"2328015443"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2012-5696","doi":"https://doi.org/10.1158/1538-7445.am2012-5696","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2012-5696","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089088185","display_name":"Ashish V. Kalra","orcid":"https://orcid.org/0000-0002-3608-7502","observed_orcids":["https://orcid.org/0000-0002-3608-7502"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashish Kalra","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054166052","display_name":"Stephan G. Klinz","orcid":"https://orcid.org/0000-0001-7354-3346","observed_orcids":["https://orcid.org/0000-0001-7354-3346"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephan Klinz","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043205772","display_name":"Nancy Paz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy Paz","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jaeyeon Kim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaeyeon Kim","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084880894","display_name":"Milind D. Chalishazar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Milind Chalishazar","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008160506","display_name":"Daryl C. Drummond","orcid":"https://orcid.org/0000-0001-6803-8863","observed_orcids":["https://orcid.org/0000-0001-6803-8863"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daryl Drummond","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020903534","display_name":"Dmitri B. Kirpotin","orcid":"https://orcid.org/0000-0002-1726-4040","observed_orcids":["https://orcid.org/0000-0002-1726-4040"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dmitri Kirpotin","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059232093","display_name":"Victor M. Moyo","orcid":"https://orcid.org/0000-0001-8470-5347","observed_orcids":["https://orcid.org/0000-0001-8470-5347"]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victor Moyo","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108270642","display_name":"Clet Niyikiza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Clet Niyikiza","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109881019","display_name":"Jonathan B. Fitzgerald","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124791","display_name":"Merrimack Pharmaceuticals (United States)","ror":"https://ror.org/034dw6775","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124791"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan Fitzgerald","raw_affiliation_strings":["1Merrimack Pharmaceuticals, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Merrimack Pharmaceuticals, Cambridge, MA","institution_ids":["https://openalex.org/I4210124791"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210124791"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"72","issue":"8_Supplement","first_page":"5696","last_page":"5696"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.04670000076293945,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.8859999775886536},{"id":"https://openalex.org/keywords/sn-38","display_name":"SN-38","score":0.921999990940094},{"id":"https://openalex.org/keywords/nanotherapeutics","display_name":"nanotherapeutics","score":0.7609999775886536},{"id":"https://openalex.org/keywords/macrophages","display_name":"macrophages","score":0.8320000171661377},{"id":"https://openalex.org/keywords/pharmacokinetic-modeling","display_name":"pharmacokinetic modeling","score":0.7360000014305115},{"id":"https://openalex.org/keywords/tumor-vascularization","display_name":"tumor vascularization","score":0.9259999990463257},{"id":"https://openalex.org/keywords/tumor-permeability","display_name":"tumor permeability","score":0.9210000038146973},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.7680000066757202},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.5099999904632568},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.8700000047683716},{"id":"https://openalex.org/keywords/topoisomerase-inhibitors","display_name":"topoisomerase inhibitors","score":0.7160000205039978}],"concepts":[{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.9652935266494751},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7127832770347595},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5948271155357361},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.546481728553772},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5155027508735657},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.4929320812225342},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.472231388092041},{"id":"https://openalex.org/C2779682216","wikidata":"https://www.wikidata.org/wiki/Q419964","display_name":"Camptothecin","level":2,"score":0.4515421390533447},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.44471338391304016},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4382087290287018},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.41136854887008667},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.4071441888809204},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.35263490676879883},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33366817235946655},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30880993604660034},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.25969398021698},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.16145211458206177},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.12127375602722168},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07275533676147461},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2012-5696","doi":"https://doi.org/10.1158/1538-7445.am2012-5696","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2012-5696","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2075819741","https://openalex.org/W2319443619","https://openalex.org/W2042635455","https://openalex.org/W2068899704","https://openalex.org/W2946346055","https://openalex.org/W1930277399","https://openalex.org/W2166885734","https://openalex.org/W3156478494","https://openalex.org/W2014811174","https://openalex.org/W2411423086"],"abstract_inverted_index":{"Abstract":[0],"MM-398":[1,46,118,126,160,182,196,262,275,298,315,330,344,361,384],"is":[2,16,272],"a":[3,13,82,121,311,332,386],"stable":[4],"nanotherapeutic":[5],"encapsulation":[6],"of":[7,25,54,117,125,135,145,148,150,159,181,195,206,215,256,261,277,281,297,314,335,360,370,383,408,413],"the":[8,94,113,143,156,254,266,290,295,350,358,364,368,381,409,414],"pro-drug":[9],"irinotecan":[10,56,69,129,248],"(CPT-11).":[11],"Irinotecan,":[12],"topoisomerase":[14],"inhibitor":[15],"currently":[17,355],"being":[18],"used":[19],"in":[20,49,70,96,232,289,374],"clinical":[21,39,91],"practice":[22],"for":[23,93,163,178,417],"treatment":[24,47],"several":[26],"indications;":[27],"however,":[28],"associated":[29],"toxicities,":[30],"mainly,":[31],"neutropenia":[32],"and":[33,58,77,84,103,127,221,263,284,316,321,338],"gastrointestinal":[34],"toxicity,":[35],"have":[36,43,80,393],"limited":[37],"its":[38],"utility.":[40],"Previously,":[41],"we":[42,119,141,183,302],"demonstrated":[44,192],"that":[45,155,269,343,391],"resulted":[48],"significantly":[50],"higher":[51,165,213],"intratumor":[52,133,167],"concentrations":[53],"both":[55],"(142-fold)":[57],"SN-38":[59,166],"(9-fold),":[60],"thereby":[61],"exhibiting":[62],"enhanced":[63,114],"anti-tumor":[64,115],"activity":[65,116,369],"compared":[66,169,200,225],"to":[67,110,131,170,201,226,242,251,264,274,348,362,396],"free":[68,128,171],"different":[71],"xenograft":[72],"models.":[73],"Multiple":[74],"phase":[75],"1":[76],"2":[78],"studies":[79,191],"established":[81],"pharmacokinetic":[83],"safety":[85],"profile.":[86],"Recent":[87],"data":[88],"support":[89,380],"continued":[90],"development":[92],"drug":[95],"various":[97,146],"indications,":[98],"including":[99],"pancreatic,":[100],"gastric,":[101],"colorectal":[102],"potentially":[104],"other":[105,371],"solid":[106],"tumors.":[107],"In":[108,189],"order":[109],"further":[111,252],"understand":[112],"developed":[120],"mechanism-based":[122],"PK":[123],"model":[124,267],"designed":[130],"predict":[132],"levels":[134,168],"SN-38.":[136],"Based":[137],"on":[138,299],"this":[139],"model,":[140],"evaluated":[142],"role":[144,255],"determinants":[147],"response":[149],"MM-398.":[151],"Sensitivity":[152],"analysis":[153,205],"revealed":[154],"local":[157,179,258,270],"activation":[158,180,271],"was":[161],"important":[162],"obtaining":[164],"irinotecan.":[172],"To":[173,293],"identify":[174],"cell":[175,237],"types":[176],"responsible":[177],"investigated":[184],"cellular":[185],"liposome":[186],"phagocytosis":[187],"ability.":[188],"vitro":[190],"preferential":[193],"uptake":[194,214],"by":[197,218,325],"phagocytic":[198],"macrophages":[199,244],"tumor":[202,207,227,259,282,351,365],"cells.":[203,228],"FACS":[204],"samples":[208],"(from":[209],"subcutaneous":[210],"xenografts)":[211],"highlighted":[212,288],"labeled":[216],"liposomes":[217],"CD11b":[219],"+":[220],"F4/80+":[222],"cells":[223],"as":[224,385],"We":[229,353],"are":[230,354],"developing":[231],"vivo":[233],"systems":[234],"using":[235],"engineered":[236],"lines":[238],"overexpressing":[239,247],"growth":[240],"factors":[241],"recruit":[243],"(CSF1)":[245],"or":[246],"conversion":[249,260],"enzymes":[250],"investigate":[253],"macrophagesin":[257],"validate":[265],"prediction":[268],"critical":[273],"mechanism":[276],"action.":[278],"The":[279],"extent":[280],"vascularization":[283],"permeability":[285],"were":[286],"also":[287],"sensitivity":[291],"analysis.":[292],"determine":[294],"effect":[296],"these":[300],"parameters,":[301],"treated":[303,328],"mice":[304],"bearing":[305],"HT29":[306],"(colorectal":[307],"cancer)":[308],"xenografts":[309],"with":[310,329],"single":[312],"dose":[313],"measured":[317],"hypoxic":[318],"markers":[319],"(CAIX)":[320],"microvessel":[322],"density":[323],"(CD31)":[324],"immunohistochemistry.":[326],"Tumors":[327],"showed":[331],"greater":[333],"degree":[334],"CD31":[336],"staining":[337],"lower":[339],"CAIX":[340],"staining,":[341],"indicating":[342],"may":[345,392],"be":[346],"able":[347],"affect":[349],"microenvironment.":[352],"evaluating":[356],"how":[357],"ability":[359],"alter":[363],"microenvironment":[366],"affects":[367],"chemotherapeutic":[372,398],"agents":[373],"combination":[375,387],"therapy.":[376],"These":[377],"findings":[378],"could":[379],"use":[382],"modality":[388],"against":[389],"tumors":[390],"acquired":[394],"resistance":[395],"traditional":[397],"agents.":[399],"Citation":[400],"Format:":[401],"{Authors}.":[402],"{Abstract":[403],"title}":[404],"[abstract].":[405],"In:":[406],"Proceedings":[407],"103rd":[410],"Annual":[411],"Meeting":[412],"American":[415],"Association":[416],"Cancer":[418,429],"Research;":[419],"2012":[420],"Mar":[421],"31-Apr":[422],"4;":[423],"Chicago,":[424],"IL.":[425],"Philadelphia":[426],"(PA):":[427],"AACR;":[428],"Res":[430],"2012;72(8":[431],"Suppl):Abstract":[432],"nr":[433],"5696.":[434],"doi:1538-7445.AM2012-5696":[435]},"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}